26. August 2019

New automated FXIII activity assay

Zedira kits


Zedira Logo                                                                                                                                                                     Transglutaminase-Newsletter | August 2019



Paving the way to a new automated FXIII activity assay!

Just recently, Technoclone (Vienna, Austria) and Zedira presented a joint poster at the 27th ISTH Congress in Melbourne, Australia. The scientists involved, Martina Leiter, Ralf Pasternack, Christian Büchold, and Nikolaus Binder concluded:
“The fully automated TECHNOFLUOR FXIII Activity assay run on the new Ceveron s100 haemostasis analyzer is an appropriate method for fast and accurate determination of this critical factor in the stabilization of blood clots. With a high degree of linearity over a wide assay range, this new assay shows excellent recovery of EQA samples, demonstrating high agreement with other FXIII activity assays on the market.”

In this context, please find below our reagents targeting FXIII (F13, plasma transglutaminase) flanked by selected coagulation products:


Selection of Factor XIII products


Assays

Art. No.NameUnitPrice

A101

FXIII-Assay Substance, Abz-NE(CAD-DNP)EQVSPLTLLK-OH10 mg520 €
F001

FXIII-Assay Kit

1 Kit575 €


Inhibitors

Art. No.NameUnitPrice

 T101

1,3,4,5-Tetramethyl-2[(2-oxo-propyl)thio] imidazolium chloride10 mg480 €
 A108

Ac-(D)-Asp-MA-Nle-Nle-Leu-Pro-Trp-Pro-OH5 mg480 €


Special product

Art. No.NameUnitPrice

 G101

Gly-Pro-Arg-Pro-amide25 mg370 €


FXIII

Art. No.NameUnitPrice

 T027

Human blood coagulation Factor XIII-A, recombinant200 µg370 €
 T070

Human Factor XIIIa, activated200 µg520 €
 T050

Human blood coagulation Factor XIII B subunit200 µg370 €


New!

Art. No.NameUnitPrice

 T222 Human alpha Thrombin, recombinant100 NIH Units185 €


Antibodies

Art. No.NameUnitPrice

 A016

Polyclonal antibody to human blood coagulation factor XIII (A-subunit)500 µg365 €
 A032

FITC-labeled polyclonal antibody to human factor XIII (A-subunit)200 µg395 €
 A074

Polyclonal antibody to human blood coagulation factor XIII (B-subunit)200 µg365 €
 A077

FITC-labeled polyclonal antibody to human factor XIII (B-subunit)200 µg395 €
 A076

DD-XLink-mab100 µg365 €



Drug Discovery at Zedira targeting FXIIIa

Zedira developed direct-acting FXIIIa blockers for safe anticoagulation. This unique and promising approach has the potential of a significant reduction in the life-threatening tendency to bleeding as provoked by current drugs. Zedira scientists used structure-assisted drug design to develop potent and selective compounds while deciphering the structure of active coagulation factor XIII.


FXIII active structure
Structure of Active Coagulation Factor XIII
In the inactive state, recombinant FXIII exists as a dimer. Upon binding of the irreversible acting blocker ZED1301 (A108) and three calcium ions per subunit, FXIII dissociates and the ß-barrel 1 and ß-barrel 2 domains undergo a remarkable shift exposing the active site (upper left). The crystal structure of FXIII in its active conformation provides detailed information on an atomic level regarding the role of calcium in the activation process. Calcium coordination affects the shape of the active site of FXIII and triggers the formation of the catalytic dyad (H342, E401).


News

Blog

Events